Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Sanderson, J.; Martyn-St James, M.; Stevens, J.; Goka, E.; Wong, R.; Campbell, F.; Selby, P.; Gittoes, N.; Davis, S. (2016)
Publisher: Elsevier
Languages: English
Types: Article
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [13] Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence Synthesis for Decision Making 3: HeterogeneitySubgroups, Meta-Regression, Bias, and Bias-Adjustment. Med Decis Mak 2013;33:618-40.
    • [14] Achana FA, Cooper NJ, Dias S, Lu G, Rice SJ, Kendrick D et al. Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise metaanalysis to network meta-analysis. Stat Med 2013;32:752-71.
    • [15] Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
    • [16] Muscoso E, Puglisi N, Mamazza C, Lo Giudice MTM, Abbate S, Santangelo P et al.
    • Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study. European Review for Medical and Pharmacological Sciences 2004;8:97- 102.
    • [17] Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Statistics and Computing 2000;10:325-37.
    • [18] R Core Team. R: A Language and Environment for Statistical Computing. [3.1.2.]. 2014. R Foundation for Statistical Computing.
    • [19] Sibylle Sturtz, Uwe Ligges, Andrew Gelman. R2WinBUGS: A Package for Running WinBUGS from R. Journal of Statistical Software 2005;12:1-16.
    • [20] Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998;7:434-55.
    • [21] Spiegelhalter DJ, Best NG, Carlin BR, van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society Series B-Statistical Methodology 2002;64:583-616.
    • [22] Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
    • [28] Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW et al. Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism 2000;85:720-6.
    • [29] Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. Journal of Bone & Mineral Research 2009;24:719-25.
    • [30] Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. New Engl J Med 2012;367:1714-23.
    • [31] Carfora E, Sergio F, Bellini P. Effect of treatment of postmenopausal osteoporosis with continuous daily oral alendronate and the incidence of fractures. Gazzetta Medica Italiano - Archivio Per Le Scienze Mediche 1998;157:105-9.
    • [32] Chesnut III CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. The American Journal of Medicine 1995;99:144-52.
    • [33] Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
    • [34] Choo C, Lukka H, Kiss A, Danjoux C. Double-blinded, placebo-controlled randomized study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in nonmetastatic prostate cancer patients undergoing radiotherapy plus 2-3 years of androgen ablation therapy. International Journal of Radiation Oncology Biology Physics 81[2 SUPPL. 1], S42. 2011. Elsevier Inc.
    • [35] Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. ARTHRITIS RHEUM 1999;42:2309-18.
    • [36] Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T et al. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures. Journal of American Medical Association 1998;280:2077-82.
    • [37] Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46.
    • [38] Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505-9.
    • [39] Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster for the bmd-mn Study Group J-Y. Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism 2000;85:1895-900.
    • [40] Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R et al. Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med 2002;136:742-6.
    • [54] Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al. Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study. J Bone Miner Res 2005;20:1315-22.
    • [55] Miller PD, Epstein S, Sedarati F, Reginster JY, Miller PD, Epstein S et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research & Opinion 2008;24:207-13.
    • [56] Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al. Alendronate for the Treatment of Osteoporosis in Men. New Engl J Med 2000;343:604-10.
    • [67] Smith BJ, Laslett LL, Pile KD, Phillips PJ, Phillipov G, Evans SM et al. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chronic Respiratory Disease 2004;1:131-7.
    • [68] Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P et al. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormonereleasing hormone-agonist therapy for prostate cancer. BJU Int 2010;106:1473-6.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article